SCHEMBL1320797

SCHEMBL1320797

CC(C)(C)OC(=O)N1CCC(n2cc(-c3cnc(-c4cccc(Cn5nc(Nc6ccccc6)ccc5=O)c4)nc3)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.51
TTK P33981 2/20 0.42
HPGDS O60760 1/20 0.40
RET P07949 1/20 0.40
TNK2 Q07912 1/20 0.40
FGFR3 P22607 1/20 0.40
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2481596 0.91 MET (0.49) MET
SCHEMBL27842065 0.90 MET (0.54) MET
SCHEMBL1320728 0.87 MET (0.47) METTTKHPGDSRETTNK2
SCHEMBL3098728 0.87 MET (0.48) METTTKHPGDSRETTNK2
SCHEMBL1317935 0.85 MET (0.52) MET
SCHEMBL13152207 0.85 MET (0.55) MET
Hydrochloric Acid SCHEMBL1321289 0.84 MET (0.51) MET
SCHEMBL1321592 0.81 MET (0.52) METTTKHPGDSRETTNK2
SCHEMBL12547684 0.80 MET (0.52) METTTKHPGDSRETTNK2
SCHEMBL15431645 0.80 MET (0.51) METTTKHPGDSRETTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
EP-2373644-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
WO-2010078910-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 MET 1/4885TTK 367/4885HPGDS 2380/4885
US-20110269765-A1 Pyridazinone derivatives MET, RET, ERBB2 MET 1/4885TTK 367/4885HPGDS 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.